{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T11:39:17Z","timestamp":1782473957624,"version":"3.54.5"},"reference-count":28,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Towa Pharmaceutical Co., Ltd"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Alzheimer\u2019s Disease"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Rivastigmine may offer greater efficacy and convenience of use with a novel formulation than previously reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the efficacy and safety of a novel, twice-weekly rivastigmine patch (TW-4752N) (TW) in Alzheimer's disease (AD) patients with mild to moderate dementia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a multicenter, phase III, double-blind study comparing TW and an existing rivastigmine transdermal patch (RT) with an open-label extension. The primary endpoint was the change in ADAS-Jcog total score at week 24 from baseline. Secondary endpoints included the ADAS-Jcog total score at weeks 8, 16, and 24.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 354 and 362 patients were available for efficacy and safety analysis, respectively. Changes in ADAS-Jcog total score at week 24 from baseline were similar between the two groups in the full analysis set with an intergroup difference of \u22120.84\u2009\u00b1\u20090.44 (95% CI, \u22121.695 to 0.016) and with the upper limit of the 95% CI being below the non-inferiority margin of 1.1, demonstrating the non-inferiority of TW. However, analysis of the per-protocol set demonstrated a significant intergroup difference in favor of TW likely suggesting a greater treatment effect with TW than with RT (p\u2009=\u20090.032). Adverse events (AEs) reported in \u22653% of patients were similar between the groups, with the only AE with an intergroup difference of \u226510% in incidence being application site pruritus (TW\/RT, 27.6%\/17.1%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>TW represents a viable alternative option of interest to patients with AD, providing comparable or potentially greater efficacy than RT and comparable safety, as well as greater convenience of use.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/13872877251401601","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T16:24:19Z","timestamp":1765297459000},"page":"1007-1019","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and safety of a novel, extended-release rivastigmine transdermal patch (TW-4752N) in patients with Alzheimer's disease: A 24-week randomized, double-blind trial with a 28-week open-label extension"],"prefix":"10.1177","volume":"109","author":[{"given":"Yu","family":"Nakamura","sequence":"first","affiliation":[{"name":"Department of Neuropsychiatry, Faculty of Medicine, Kagawa University, Kagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3495-2995","authenticated-orcid":false,"given":"Takaya","family":"Kurokawa","sequence":"additional","affiliation":[{"name":"Clinical Development Department, Pharmaceutical Development Unit, R&amp;D Division, Towa Pharmaceutical Co., Ltd, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Terashima","sequence":"additional","affiliation":[{"name":"Clinical Development Department, Pharmaceutical Development Unit, R&amp;D Division, Towa Pharmaceutical Co., Ltd, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Nishimura","sequence":"additional","affiliation":[{"name":"Clinical Development Department, Pharmaceutical Development Unit, R&amp;D Division, Towa Pharmaceutical Co., Ltd, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,12,9]]},"reference":[{"key":"e_1_3_3_2_2","unstructured":"Prince MM Comas-Herrera A Knapp M et al. World Alzheimer Report 2016: Improving healthcare for people living with dementia: coverage quality and costs now and in the future. London: Alzheimer\u2019s Disease International 2016 p. 131."},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25245789"},{"key":"e_1_3_3_4_2","first-page":"211","article-title":"Efficacy and safety of donepezil, galantamine and rivastigmine for the treatment of Alzheimer\u2019s disease: a systematic review and meta-analysis","volume":"3","author":"Hansen RA","year":"2008","unstructured":"Hansen RA, Gartlehner G, Webb AP, et al. Efficacy and safety of donepezil, galantamine and rivastigmine for the treatment of Alzheimer\u2019s disease: a systematic review and meta-analysis. Clin Interv Aging 2008; 3: 211\u2013225.","journal-title":"Clin Interv Aging"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2318-5-3"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.318.7184.633"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1177\/1533317510365344"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2009.02052.x"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-5949.2009.00119.x"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200115050-00004"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1185\/030079903125002450"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1177\/1533317509333037"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2009.02253.x"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-014-2002-3"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1159\/000501364"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1017\/S1041610210001985"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.2174\/1567205019666220823105059"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1159\/000439269"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2013.13020179"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1975.00490510088009"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1159\/000486956"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1159\/000513485"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-190767"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.3390\/geriatrics8010012"},{"key":"e_1_3_3_26_2","first-page":"647","article-title":"Development of a Japanese version of Alzheimer\u2019s disease assessment scale (ADAS)","volume":"3","author":"Honma A","year":"1992","unstructured":"Honma A, Fukuzawa K, Tsukada Y, et al. Development of a Japanese version of Alzheimer\u2019s disease assessment scale (ADAS). Jpn J Geriatr Psychiatry 1992; 3: 647\u2013655. (in Japanese).","journal-title":"Jpn J Geriatr Psychiatry"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.87802"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1159\/000328929"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1177\/13872877241292018"}],"container-title":["Journal of Alzheimer\u2019s Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13872877251401601","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/13872877251401601","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13872877251401601","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T10:53:04Z","timestamp":1781779984000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/13872877251401601"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,9]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1177\/13872877251401601"],"URL":"https:\/\/doi.org\/10.1177\/13872877251401601","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,9]]}}}